Q4 2024
Released Feb 28, 2025, before the open
10-K filed Feb 28, 2025, 59 days after period end · 0001628280-25-008884
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.18M$2.18M derived— vs Q4 2023+944.5% vs Q3 2024
Net Income-$42.28M-$42.28M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$44,222,000N/M
Operating Cash Flowderived$16,245,000N/M
Free Cash Flowderived$14,454,000N/M
Margins · derived
Operating margin-2025.7%
Net margin-1936.6%
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $2.18M | $0.00 | — | — |
| Net Income | -$42.28M | -$65.64M | -$39.28M | -$62.91M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR